Squarepoint Ops LLC Has $1.13 Million Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Squarepoint Ops LLC lessened its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 67.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 39,555 shares of the specialty pharmaceutical company's stock after selling 82,918 shares during the quarter. Squarepoint Ops LLC owned approximately 0.12% of Collegium Pharmaceutical worth $1,133,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of COLL. Barclays PLC increased its stake in Collegium Pharmaceutical by 152.2% in the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company's stock valued at $2,899,000 after buying an additional 45,291 shares during the last quarter. KBC Group NV grew its holdings in shares of Collegium Pharmaceutical by 72.5% in the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock valued at $67,000 after acquiring an additional 982 shares in the last quarter. Caprock Group LLC increased its position in shares of Collegium Pharmaceutical by 6.7% in the fourth quarter. Caprock Group LLC now owns 8,698 shares of the specialty pharmaceutical company's stock valued at $249,000 after acquiring an additional 543 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Collegium Pharmaceutical by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company's stock worth $196,000 after acquiring an additional 642 shares in the last quarter. Finally, Meritage Portfolio Management boosted its position in Collegium Pharmaceutical by 5.0% during the fourth quarter. Meritage Portfolio Management now owns 20,755 shares of the specialty pharmaceutical company's stock valued at $595,000 after purchasing an additional 979 shares during the last quarter.

Collegium Pharmaceutical Stock Performance

COLL traded up $0.04 on Tuesday, reaching $29.35. The company had a trading volume of 167,526 shares, compared to its average volume of 420,920. The stock has a market cap of $943.07 million, a P/E ratio of 12.65 and a beta of 0.63. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical, Inc. has a fifty-two week low of $23.23 and a fifty-two week high of $42.29. The company's fifty day moving average is $28.00 and its 200 day moving average is $29.60.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.50 by ($0.01). The firm had revenue of $177.76 million for the quarter, compared to the consensus estimate of $174.96 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The company's revenue was up 22.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.45 EPS. As a group, analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Insider Activity at Collegium Pharmaceutical

In other news, EVP Shirley R. Kuhlmann sold 26,067 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $28.50, for a total transaction of $742,909.50. Following the completion of the sale, the executive vice president now owns 108,137 shares of the company's stock, valued at approximately $3,081,904.50. This represents a 19.42% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Colleen Tupper sold 977 shares of the stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $30.00, for a total transaction of $29,310.00. Following the sale, the chief financial officer now owns 164,269 shares in the company, valued at $4,928,070. This represents a 0.59% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 41,693 shares of company stock worth $1,211,794. Corporate insiders own 2.51% of the company's stock.

Analyst Ratings Changes

Several research firms have weighed in on COLL. Needham & Company LLC reaffirmed a "buy" rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. Wall Street Zen downgraded shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday, April 19th. HC Wainwright restated a "buy" rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Finally, Piper Sandler reiterated a "neutral" rating and set a $37.00 target price (up from $36.00) on shares of Collegium Pharmaceutical in a research note on Friday, May 9th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $43.80.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.